Dr. Arjun Tarakad
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 312
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Texas Medical School at Houston
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license Q8365 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Harris Health Houston, TX
- Houston Methodist West Hospital Houston, TX
- Baylor St Lukes Medical Center Houston, TX
Medical groups
- Baylor College of Medicine (1,240 clinicians)
- Baylor College of Medicine (809 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 312
- Services billed
- 44,575
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 37,260 | 52 |
| Injection, incobotulinumtoxin a, 1 unit | 8,100 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 448 | 243 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 89 | 49 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 88 | 32 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 75 | 33 |
| Injection of chemical for paralysis of nerve muscles on side of face | 64 | 25 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 56 | 24 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 47 | 40 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Houston, TX | 634 |
| Rytary (carbidopa/levodopa) Other prescribers in Houston, TX | 343 |
| Gabapentin Other prescribers in Houston, TX | 158 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Houston, TX | 133 |
| Austedo (deutetrabenazine) Other prescribers in Houston, TX | 99 |
| Amantadine (amantadine hcl) Other prescribers in Houston, TX | 96 |
| Clonazepam Other prescribers in Houston, TX | 88 |
| Xadago (safinamide mesylate) | 86 |
| Memantine Hcl Other prescribers in Houston, TX | 77 |
| Rivastigmine Other prescribers in Houston, TX | 71 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 9 payments worth $511 in total to this clinician.
| Medtronic, Inc. | $275 |
|---|---|
| Merz Pharmaceuticals, LLC | $149 |
| Abbott Laboratories | $66.91 |
| Boston Scientific Corporation | $20.70 |
| Food and Beverage | $499 |
|---|---|
| Travel and Lodging | $11.88 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Medtronic, Inc. Sep 24, 2025 | Travel and Lodging PERCEPT PC BRAINSENSE · Deep Brain Neurostimulation · travel to Houston, TX · in-kind | $8.98 |
| Medtronic, Inc. Sep 23, 2025 | Travel and Lodging PERCEPT PC BRAINSENSE · Deep Brain Neurostimulation · travel to Houston, TX · in-kind | $2.90 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $667,931 in research payments for these studies, mostly to the institutions running them.
- A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease
Genentech, Inc. - Phase II study in early stage Parkinson s Disease Patients
Roche Tcrc, Inc. - Open-label Trial in Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04760769 - Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2)
AbbVie Inc. - Open-label Trial in Parkinson s Disease (PD) (TEMPO-4)
AbbVie Inc. - Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
AbbVie Inc. · Completed · NCT04542499 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
AbbVie Inc. · Completed · NCT04379050 - M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease
AbbVie Inc. - Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.